- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00982722
Vitamin D Supplementation After Parathyroid Surgery
February 26, 2019 updated by: Inga-Lena Nilsson, Karolinska University Hospital
Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism
A randomised double blind clinical trial, accepted by the Medical Products Agency and registered in the European Clinical Trials Database.
Aims to evaluate the prevalence of vitamin D deficiency in a pHPT population in relation to gender and age, the correlation between vitamin D status, pre- and postoperative parathyroid hormone level and bone density and the correlation between vitamin D status, metabolic, cardiovascular risk factors and QoL aspects before and after parathyroid adenomectomy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
150 PHPT patients were randomized six weeks after surgery, 75 into each group, to 1 year of oral treatment with either calcium carbonate 1 g (500 mg twice daily) alone or calcium carbonate 1 g combined with cholecalciferol 1600 IU (800 IU twice daily).
Exclusion criteria were age under 18, manifest osteoporosis at PHPTdiagnosis, persistent hypercalcemia after surgery, postoperative hypocalcemia requiring vitamin D treatment, glomerular filtration rate (GFR) below 40 ml/min, pregnancy, breast feeding, or logistical difficulties, for example living far from the hospital.
Included patients had to withdraw any current supplementation with calcium and vitamin D during the study period.
All tablets were identical in appearance, the tins were numbered and randomization followed a list compiled by an independent clinical research support organization.
The time for randomization was chosen to make sure that the PHPT patients were cured before starting the study medication.
Nearly three-quarters of the patients were randomized within 6 weeks after PTX.The primary end point was the change in PTH after PTX and treatment with the study medication.
Secondary end points were vitamin D levels, insulin resistance, blood pressure and other cardiovascular risk factors, biochemical markers of bone turnover, bone mineral density and self estimated health related quality of life (SF- 36).
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden, SE-17176
- Karolinska University Hospital
-
Stockholm, Sweden, 17176
- Karolinska UH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Primary hyperparathyroidism subjected to parathyroid surgery
Exclusion Criteria:
- Renal insufficiency
- Severe osteoporosis
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cholecalciferol and calcium carbonate
cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2
|
calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Other Names:
|
Active Comparator: calciumcarbonate
calcium carbonate 500 mg x 2
|
cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
postoperative parathyroid hormone level
Time Frame: 3 months
|
PTH
|
3 months
|
ambulatory blood pressure
Time Frame: one year
|
24h blood pressure
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
bone mineral density
Time Frame: one year
|
DEXA
|
one year
|
25-OH Vitamin D
Time Frame: 3 months
|
s-25OHD
|
3 months
|
Calcium
Time Frame: 6 weeks
|
ionized calcium
|
6 weeks
|
Quality of life-self estimating formularies
Time Frame: one year
|
SF36
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Inga-Lena Nilsson, MD, Ass prof, Karolinska UH
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Norenstedt S, Pernow Y, Zedenius J, Nordenstrom J, Saaf M, Granath F, Nilsson IL. Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study. J Bone Miner Res. 2014 Apr;29(4):960-7. doi: 10.1002/jbmr.2102.
- Norenstedt S, Pernow Y, Brismar K, Saaf M, Ekip A, Granath F, Zedenius J, Nilsson IL. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol. 2013 Oct 21;169(6):795-804. doi: 10.1530/EJE-13-0547. Print 2013 Dec.
- Aberg V, Norenstedt S, Zedenius J, Saaf M, Nordenstrom J, Pernow Y, Nilsson IL. Health-related quality of life after successful surgery for primary hyperparathyroidism: no additive effect from vitamin D supplementation: results of a double-blind randomized study. Eur J Endocrinol. 2015 Feb;172(2):181-7. doi: 10.1530/EJE-14-0757. Epub 2014 Nov 20.
- Nilsson IL, Norenstedt S, Granath F, Zedenius J, Pernow Y, Larsson TE. FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery. 2016 Jan;159(1):211-7. doi: 10.1016/j.surg.2015.06.057. Epub 2015 Oct 2.
- Nilsson IL, Norenstedt S, Zedenius J, Pernow Y, Branstrom R. Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy. Surgery. 2017 Aug;162(2):429-436. doi: 10.1016/j.surg.2017.02.017. Epub 2017 May 15.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
May 4, 2018
Study Completion (Actual)
May 4, 2018
Study Registration Dates
First Submitted
September 22, 2009
First Submitted That Met QC Criteria
September 22, 2009
First Posted (Estimate)
September 23, 2009
Study Record Updates
Last Update Posted (Actual)
February 28, 2019
Last Update Submitted That Met QC Criteria
February 26, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Parathyroid Diseases
- Hyperparathyroidism
- Hyperparathyroidism, Primary
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Antacids
- Vitamin D
- Cholecalciferol
- Calcium
- Calcium, Dietary
- Calcium Carbonate
Other Study ID Numbers
- Eudra CT 2007-003691-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Hyperparathyroidism
-
Postgraduate Institute of Medical Education and...UnknownPrimary Hyperparathyroidism (PHPT)India
-
Nantes University HospitalCompleted
-
Rambam Health Care CampusWithdrawnMultigland Disease in Primary HyperparathyroidismIsrael
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedTotal Thyroidectomy | Bilateral Neck Exploration for Primary HyperparathyroidismUnited Kingdom
-
Nantes University HospitalInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
Brigham and Women's HospitalCompletedPrimary HyperparathyroidismUnited States
-
University Hospital Inselspital, BerneCompletedPrimary HyperparathyroidismSwitzerland
-
EFSTATHIOS CHRONOPOULOSCompletedPrimary Hyperparathyroidism
-
M.D. Anderson Cancer CenterUnknownPrimary HyperparathyroidismUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownPrimary Hyperparathyroidism
Clinical Trials on calcium carbonate
-
Unity Health TorontoCanadian Institutes of Health Research (CIHR)CompletedEnd-stage Renal DiseaseCanada
-
BayerRecruitingHealthy Volunteers | Heartburn | Indigestion | Stomach Acid Related Symptoms | Nocturnal Stomach Acid Related SymptomsUnited Kingdom
-
China Medical University HospitalRecruitingRheumatoid Arthritis | Osteopenia or OsteoporosisTaiwan
-
Harvard School of Public Health (HSPH)Ifakara Health Institute; St. John's Research Institute; Africa Academy for Public...CompletedPregnancy RelatedTanzania, India
-
BayerCompleted
-
University of Colorado, DenverRecruitingAging | Vascular Stiffness | Vascular DilationUnited States
-
Gary StrikerCompleted
-
Integrative Health Technologies, Inc.UnknownOsteopenia, OsteoporosisUnited States
-
University College, LondonActive, not recruitingChronic Kidney DiseasesUnited Kingdom
-
Purdue UniversityCompletedOsteoporosisUnited States